NEW YORK, Nov. 8, 2016 /PRNewswire/ -- "Oncology (1985-2016) - 157 cancer drugs -Ranking and detailed regulatory approval profiles" is a comprehensive drug ranking and profiling report that ranks cancer drugs based on total approvals and unique approvals received in US, Europe and Japan. It provides the regulatory approval details of each drug for the past 30 years (1985-2016) in both the tabular and (an interesting) infographic formats. Additionally, the basic drug-specific information such as first approvals, breakthrough, orphan designations, black box warnings, etc., is also presented along with negative developments of drugs recalled, discontinued and withdrawn. We have screened and segmented 157 drugs (from a list of 250 approved cancer drugs) based on the criteria of at least one new or additional approval in the past decade. This report gives detailed information about these drugs and their approval histories from all the three regulatory bodies, namely, the US-based United States Food and Drugs Authority (USFDA), Europe-based European Medicines Agency (EMA) and Japan-based Pharmaceuticals and Medical Devices Agency (PMDA). The report is divided into two broader sections (Ranking and Drug Profiles) and several sub-sections. We have sequenced 157 drugs into six segments based on total number of approvals: Segment A - 25+ approvals; Segment B - 15 to 24 approvals; Segment C - 10 to 14 approvals; Segment D - 5 to 9 approvals; Segment E - 2 to 4 approvals; Segment F - only one approval. Similarly, drugs are ranked in various segments based on unique approvals. Each drug in the drug profile section is described in the following three parts: Part 1 - basic information, Part 2 - approval timeline infographic and Part 3 - approval history tables. Part 1: The basic information section covers:Trade names: Drugs are often known by different brand names (trade names) in different geographies. For instance, Rituxan is the trade name for Rituximab in the US, whereas it is known as Mabthera in Europe. We have presented each drug's trade name used in different geographies in our report. Companies involved in marketing: Drugs are often sold or marketed in different geographies by different companies. For instance, Aranesp is marketed in the US and Europe by Amgen, whereas in Japan it is marketed by Kyowa Hakko Kirin. Active pharmaceutical ingredient: Active pharmaceutical ingredients (API) are the active ingredients in medications, carried by the excipient. In each case, the drug has an API and it has a trade name, by which it is known in the market. For instance, Revlimid is the brand or trade name, whereas lenalidomide is its API.